Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE vs Conventional TACE in HCC
NCT04048317Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Implantable Devices, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of HepaSphere Microspheres + doxorubicin hydrochloride in hepatocellular carcinoma (HCC) (2 arms), sponsored by Assiut University. Primary endpoint: Effectiveness of drug-eluting bead trans-arterial chemo-embolization (Tumor response). Status: unknown.
02
Drugs
HepaSphere Microspheres + doxorubicin hydrochloride
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04048317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048317.